Sigma Planning Corp Lantern Pharma Inc. Transaction History

Sigma Planning Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 01, 2025	BUY	$3.3 - $5.42 $660 - $1,084	200 Added 0.7%	28,650 $101,000
Q4 2024 Feb 03, 2025	SELL	$2.9 - $4.26 $580 - $852	-200 Reduced 0.7%	28,450 $90,000
Q3 2024 Nov 01, 2024	BUY	$3.42 - $4.83 $855 - $1,207	250 Added 0.88%	28,650 $105,000
Q2 2024 Aug 05, 2024	BUY	$3.91 - $9.51 $6,060 - $14,740	1,550 Added 5.77%	28,400 $132,000
Q1 2024 May 01, 2024	BUY	$3.73 - $10.65 $55,856 - $159,483	14,975 Added 126.11%	26,850 $236,000
Q4 2023 Feb 01, 2024	SELL	$2.48 - $4.39 $15,500 - $27,437	-6,250 Reduced 34.48%	11,875 $50,000
Q2 2023 Aug 01, 2023	BUY	$4.56 - $6.02 $3,875 - $5,117	850 Added 4.92%	18,125 $102,000
Q1 2023 May 05, 2023	SELL	$4.3 - $6.2 $107 - $155	-25 Reduced 0.14%	17,275 $83,000
Q4 2022 Jan 24, 2023	SELL	$4.19 - $6.04 $838 - $1,208	-200 Reduced 1.14%	17,300 $0
Q3 2022 Nov 10, 2022	SELL	$4.59 - $6.5 $459 - $650	-100 Reduced 0.57%	17,500 $84,000
Q4 2021 Feb 02, 2022	BUY	$7.11 - $11.04 $125,136 - $194,303	17,600 New	17,600 $140,000

2.24M

17.1K

1.3K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $54M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.